-
Glaukos reported third quarter 2026 sales of US$211.03 million and returned to profitability, raised full year 2026 net sales guidance to US$775 million to US$785 million, and issued preliminary 2027 net sales guidance of US$1 billion, alongside a shift from the S&P 600 to the S&P 400 and its Health Care sector index.
-
The combination of stronger earnings, higher sales targets and index reclassification moves Glaukos into a mid cap benchmark set that can attract a different mix of institutional investors. It also highlights the operational importance of scaling products like iDose TR and Epioxa to support the larger revenue base that management is targeting.
-
We will now look at how Glaukos's upgraded 2026 and preliminary 2027 sales outlook could reshape the existing investment narrative.
Scan how Glaukos' move into the S&P 400 fits alongside other mid cap opportunities by reviewing the hand picked list of solid balance sheet and fundamentals (24 results) in this segment of the market.
Glaukos Investment Narrative Recap
To own Glaukos, you need to be comfortable with a focused bet on interventional eye care. The story leans on iDose TR and Epioxa building into large, procedure driven franchises while reimbursement frameworks catch up. The raised 2026 guidance and preliminary 2027 sales outlook sharpen that lens, but the thesis still lives and dies on execution in the operating room.
In the near term, the key catalyst is whether Glaukos can convert surgeon and patient interest into consistent procedure volumes as payer workflows mature. The biggest operational risk remains reimbursement friction around iDose TR and Epioxa, where restrictive coverage decisions or prolonged prior authorization drag could offset the positive signal from stronger recent earnings.
The 2026 and 2027 sales guidance is the announcement that most closely anchors this index move. Management now expects 2026 net sales of US$775 million to US$785 million and has outlined preliminary 2027 net sales of US$1 billion. Those figures frame what "mid cap" now means for Glaukos and give investors a clearer revenue scale to underwrite.
What matters is how that outlook intersects with the catalysts you are watching. Sustained adoption of iDose TR, the build out of Epioxa treatment and detection infrastructure, and progress across the glaucoma and corneal R&D pipeline all need to justify those higher sales targets. Any stumble on reimbursement, competition or payer processes would sit uncomfortably next to such an ambitious top line goal.
Glaukos' narrative projects US$1.2b revenue and US$138.6 million earnings by 2029. This rests on analysts modeling 25.7% yearly revenue growth and an earnings swing of about US$326.6 million, from a loss of US$188.0 million today to the 2029 consensus figure.
Uncover how Glaukos' fair value indicates an 11% potential downside to its current price that leaves little room for error.
Exploring Other Perspectives
One alternate take on Glaukos puts the O2N network and very high gross margin profile at the center of the story. Before this latest guidance and index shift, the most optimistic analysts were already modeling revenue reaching about US$1.7b and earnings of roughly US$247.7 million by 2029. That is far above the consensus view. These projections were set without factoring in the fresh 2026 and 2027 targets or the move into the S&P 400, so you may see those narratives adjust. Use this spread in expectations as a reminder to compare several viewpoints before deciding how Glaukos fits your own portfolio goals.
Explore 3 other Glaukos fair value estimates , including one that suggests the potential for as much as 63% upside from the current price.
Form Your Own Verdict
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
-
A great starting point for your Glaukos research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
-
See our latest analysis for Glaukos. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Glaukos' overall financial health at a glance.
Looking for more investment ideas beyond Glaukos?
Once you have formed a view on Glaukos, it can help to widen the lens and compare it with other opportunities that fit different risk, income and balance sheet profiles.
-
If you want potential upside with strict quality filters, scan the 39 high quality undervalued stocks that currently pass the Simply Wall St Screener.
-
For investors who care most about resilient balance sheets, review the list of solid balance sheet and fundamentals (24 results) highlighted by the screener tool.
-
If you prefer to focus on income, shortlist stocks from the 8 dividend fortresses that may suit a yield oriented approach.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GKOS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
